Vaccine Contract Manufacturing Market size is expected to reach USD 4.0 billion by 2025, A vaccine provides active acquired immunity to a disease. The demand for vaccine contract manufacturing is increasing in the market. Vaccine manufacturing is a complex process, in which effectivity, safety and consistency are the most important part for the manufacturers. It offers many services such as production process, cell line development, construction & operation of manufacturing product, process optimization, fermentation and analytical characterization, which fuels the market growth in the coming years. The vaccine contract manufacturing market registering a CAGR of 9.3% in the upcoming period as the scope, product types, and its applications are increasing across the globe.
Vaccine
contract services offer cost-saving benefits to their clients. Also, they help
to save time in operations & management of a research and production
facility. The growing demand for vaccine development from the private sector as
well as governments in developing and industrialized countries is expected to
witness significant growth of the market in the coming years.
Request Sample Copy of This Market Research @
In
the market, various types of vaccines are available such as inactivated
vaccines, attenuated vaccines, toxoid-based vaccines, subunit-based vaccines,
DNA-based vaccines, recombinant vector vaccines, synthetic vaccines and others.
The “attenuated vaccines” is expected to hold the large market share in the
upcoming period due to their ability to elicit strong and antibody responses.
These vaccines offer lifetime immunities with just one or two doses. Moreover,
proper handling conditions, especially with respect to storage and maintenance
will continue to drive the segment in the coming years.
In
addition, in the market some single as well as combination vaccine are
available. The single vaccine such as influenza virus, ebola virus, chickenpox,
smallpox, polio, tetanus, tuberculosis and others could be explored in vaccine
contract manufacturing industry. The factors that play an important role in the
growth of market include increasing demand, growing population, increasing
urbanization & industrialization, growing pharmaceutical industry, increase
in the number of countries demanding the introduction of vaccines, stringent
government rules & regulations and increasing awareness about vaccination
& its benefits in developing countries. Moreover, increasing prevalence of
various bacterial and viral infections is a main factor drive the growth of the
vaccine contract manufacturing market in the next couple of years.
Browse Full Research Report @
https://www.millioninsights.com/industry-reports/vaccine-contract-manufacturing-market
However,
high cost of vaccination, regulatory challenges and patent expiration in recent
times are negatively impacting the growth of vaccine contract manufacturing
industry. The market is widely analyzed based on different regional factors
such as gross domestic product (GDP), demographics, acceptance, inflation rate
and others. The market is categorized based on vaccine type, product type,
workflow, application and geography.
The
market is classified into workflow such as downstream and upstream. The
“downstream” segment is further segregated into fill & finish operations,
packaging and analytical & QC studies whereas the segment “upstream” is
segmented into mammalian expression systems, yeast expression systems,
bacterial expression systems, baculovirus/insect expression systems and others.
Vaccine production requires skilled personnel for downstream as well as
upstream processing. The “downstream” segment is expected to witness
significant growth in the coming years owing to the robust demand for
downstream processing and sophisticated equipment for efficient product
recovery.
North
America is accounting large market share in the years to come owing to
widespread manufacturing of vaccines in this region, coupled with growing
presence of large number of biopharmaceutical facilities. State and the other
laws pertaining to development of vaccines & other biologics, particularly
in Canada and U.S. are expected to boost the market growth in this region. On
the other hand, Asia Pacific is projected to grow at a higher CAGR in the next
couple of years due to growing population, improving infrastructure in several
developing countries, and growing pharmaceutical industry.
The
key players contributing to the robust development of the vaccine contract
manufacturing market include Lonza, Paragon Bioservices Inc., Ajinomoto Althea
Inc., FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Merck KGaA, Cytovance
Biologics, Catalent Inc., IDT Biologika GmbH, Albany Molecular Research Inc.,
PRA Health Sciences, ICON plc., Pharmaceutical Product Development, LLC, and
Cobra Bio. The major market players are focusing on inorganic growth to sustain
themselves amidst fierce competition. As such, mergers, acquisitions, and joint
ventures are the need of the hour.
Comments
Post a Comment